Immunoediting of cancers may lead to epithelial to mesenchymal transition

Journal of Immunology

Volumn 177, Issue 3, 2006, Pages 1526-1533

  Knutson, Keith L ^a,d   Lu, Hailing ^b   Stone, Brad ^c   Reiman, Jennifer M ^a   Behrens, Marshall D ^a   Prosperi, Christine M ^a   Gad, Ekram A ^b   Smorlesi, Arianna ^b,e   Disis, Mary L ^b  

^a MAYO CLINIC   (United States)

^b Center for Translational Medicine in Women's Health   (United States)

^c BENAROYA RESEARCH INSTITUTE   (United States)

^d Mayo Clinic   (United States)

^e INRCA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

TUMOR VACCINE;

ADOLESCENT; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIGEN EXPRESSION; ARTICLE; BREAST CANCER; CELL DIFFERENTIATION; CELL INVASION; CELL STRUCTURE; EPITHELIAL MESENCHYMAL TRANSITION; GENE EXPRESSION; IMMUNE RESPONSE; IMMUNOEDITING; IMMUNOLOGICAL TOLERANCE; INNATE IMMUNITY; MAJOR HISTOCOMPATIBILITY COMPLEX; MOUSE; NONHUMAN; ONCOGENE NEU; PRIORITY JOURNAL; TISSUE MICROARRAY; TRANSGENIC MOUSE; TUMOR IMMUNITY;

EID: 33746215279     PISSN: 00221767     EISSN: None     Source Type: Journal    
DOI: 10.4049/jimmunol.177.3.1526     Document Type: Article

References (35)

1. Dunn, G. P., A. T. Bruce, H. Ikeda, L. J. Old, and R. D. Schreiber. 2002. Cancer immunoediting: from immunosurveillance to tumor escape. Nat. Immunol. 3: 991-998.
2. Knutson, K. L., B. Almand, Y. Dang, and M. L. Disis. 2004. Neu antigen-negative variants can be generated after neu-specific antibody therapy in neu transgenic mice. Cancer Res. 64: 1146-1151.
3. + T cell clones for the treatment of patients with metastatic melanoma: in vivo persistence, migration, and antitumor effect of transferred T cells. Proc. Natl. Acad. Sci. USA 99: 16168-16173.
4. Sanchez-Perez, L., T. Kottke, R. M. Diaz, A. Ahmed, J. Thompson, H. Chong, A. Melcher, S. Holmen, G. Daniels, and R. G. Vile. 2005. Potent selection of antigen loss variants of B16 melanoma following inflammatory killing of melanocytes in vivo. Cancer Res. 65: 2009-2017.
5. Zhou, G., Z. Lu, J. D. McCadden, H. I. Levitsky, and A. L. Marson. 2004. Reciprocal changes in tumor antigenicity and antigen-specific T cell function during tumor progression. J. Exp. Med. 200: 1581-1592.
6. Khong, H. T., Q. J. Wang, and S. A. Rosenberg. 2004. Identification of multiple antigens recognized by tumor-infiltrating lymphocytes from a single patient: tumor escape by antigen loss and loss of MHC expression. J. Immunother. 27: 184-190.
7. + T cell clone leads to immunoselection of human melanoma antigen-loss variants in SCID mice. Eur. J. Immunol. 33: 556-566.
8. Madjd, Z., I. Spendlove, S. E. Pinder, I. O. Ellis, and L. G. Durrant. 2005. Total loss of MHC class I is an independent indicator of good prognosis in breast cancer. Int. J. Cancer 117: 248-255.
9. Bissell, M. J., and M. A. Labarge. 2005. Context, tissue plasticity, and cancer: are tumor stem cells also regulated by the microenvironment? Cancer Cell 7: 17-23.
10. + T cells to the antitumor immune response. J. Exp. Med. 201: 1591-1602.
11. Manjili, M. H., H. Arnouk, K. L. Knutson, M. Kmieciak, M. L. Disis, J. R. Subjeck, and A. L. Kazim. 2006. Emergence of immune escape variant of mammary tumors that has distinct proteomic profile and a reduced ability to induce "danger signals". Breast Cancer Res. Treat. 96: 233-241.
12. Guy, C. T., M. A. Webster, M. Schaller, T. J. Parsons, R. D. Cardiff, and W. J. Muller. 1992. Expression of the neu protooncogene in the mammary epithelium of transgenic mice induces metastatic disease. Proc. Natl. Acad. Sci. USA 89: 10578-10582.
13. Ercolini, A. M., J.-P. Machiels, Y. C. Chen, J. E. Slansky, M. Giedlen, R. T. Reilly, and E. M. Jaffee. 2003. Identification and characterization of the immunodominant rat HER-2/neu MHC class 1 epitope presented by spontaneous mammary tumors from HER-2/neu-transgenic mice. J. Immunol. 170: 4273-4280.
14. Reilly, R. T., J.-P. Machiels, L. A. Emens, A. M. Ercolini, F. I. Okoye, R. Y. Lei, D. Weintraub, and E. M. Jaffee. 2001. The collaboration of both humoral and cellular HER-2/neu-targeted immune responses is required for the complete eradication of HER-2/neu-expressing tumors. Cancer Res. 61: 880-883.
15. Reilly, R. T., M. B. Gottlieb, A. M. Ercolini, J.-P. Machiels, C. E. Kane, F. I. Okoye, W. J. Muller, K. H. Dixon, and E. M. Jaffee. 2000. HER-2/neu is a tumor rejection target in tolerized HER-2/neu transgenic mice. Cancer Res. 60: 3569-3576.
16. Knutson, K. L., and M. L. Disis. 2001. Expansion of HER2/neu-specific T cells ex vivo following immunization with a HER2/neu peptide-based vaccine. Clin. Breast Cancer 2: 73-79.
17. Knutson, K. L., Y. Dang, H. Lu, J. Lukas, B. Almand, E. Gad, E. Azeke, and M. L. Disis. 2006. IL-2 immunotoxin therapy modulates tumor-associated regulatory T cells and leads to lasting immune-mediated rejection of breast cancers in neu-transgenic mice. J. Immunol. In press.
18. Drebin, J. A., V. C. Link, and M. I. Greene. 1988. Monoclonal antibodies reactive with distinct domains of the neu oncogene-encoded p 185 molecule exert synergistic anti-tumor effects in vivo. Oncogene 2: 273-277.
19. Knutson, K. L., and M. L. Disis. 2004. IL-12 enhances the generation of tumour antigen-specific Th1 CD4 T cells during ex vivo expansion. Clin. Exp. Immunol. 135: 322-329.
20. Huber, M. A., N. Kraut, and H. Beug. 2005. Molecular requirements for epithelial-mesenchymal transition during tumor progression. Curr. Opin. Cell Biol. 17: 548-558.
21. Lame, L., and A. Bellacosa. 2005. Epithelial-mesenchymal transition in development and cancer: role of phosphatidylinositol 3′ kinase/AKT pathways. Oncogene 24: 7443-7454.
22. Thomson, S., E. Buck, F. Petti, G. Griffin, E. Brown, N. Ramnarine, K. K. Iwata, N. Gibson, and J. D. Haley. 2005. Epithelial to mesenchymal transition is a determinant of sensitivity of non-small-cell lung carcinoma cell lines and xenografts to epidermal growth factor receptor inhibition. Cancer Res. 65: 9455-9462.
23. Sleeman, K. E., H. Kendrick, A. Ashworth, C. M. Isacke, and M. J. Smalley. 2006. CD24 staining of mouse mammary gland cells defines luminal epithelial, myoepithelial/basal and non-epithelial cells. Breast Cancer Res. 8: R7.
24. Hay, E. D. 1995. An overview of epithelio-mesenchymal transformation. Acta Anat. (Basel) 154: 8-20.
25. Gotzmann, J., M. Mikula, A. Eger, R. Schulte-Hermann, R. Foisner, H. Beug, and W. Mikulits. 2004. Molecular aspects of epithelial cell plasticity: implications for local tumor invasion and metastasis. Mutat. Res. 566: 9-20.
26. Thiery, J. P. 2003. Epithelial-mesenchymal transitions in development and pathologies. Curr. Opin. Cell Biol. 15: 740-746.
27. Vihinen, P., R. Ala-aho, and V. M. Kahari. 2005. Matrix metalloproteinases as therapeutic targets in cancer. Curr. Cancer Drug Targets 5: 203-220.
28. Kang, H., G. Watkins, C. Parr, A. Douglas-Jones, R. E. Mansel, and W. G. Jiang. 2005. Stromal cell derived factor-1: its influence on invasiveness and migration of breast cancer cells in vitro, and its association with prognosis and survival in human breast cancer. Breast Cancer Res. 7: R402-R410.
29. Dudley, M. E., J. R. Wunderlich, J. C. Yang, R. M. Sherry, S. L. Topalian, N. P. Restifo, R. E. Royal, U. Kammula, D. E. White, S. A. Mavroukakis, et al. 2005. Adoptive cell transfer therapy following non-myeloablative but lymphodepleting chemotherapy for the treatment of patients with refractory metastatic melanoma. J. Clin. Oncol. 23: 2346-2357.
30. Vincent-Salomon, A., and J. P. Thiery. 2003. Host microenvironment in breast cancer development: epithelial-mesenchymal transition in breast cancer development. Breast Cancer Res. 5: 101-106.
31. Bates, R. C., and A. M. Mercurio. 2003. Tumor necrosis factor-α stimulates the epithelial-to-mesenchymal transition of human colonie organoids. Mol. Biol. Cell 14: 1790-1800.
32. Ardizzoia, A., P. Lissoni, F. Brivio, E. Tisi, M. S. Perego, M. G. Grassi, S. Pittalis, S. Crispino, S. Barni, and G. Tancini. 1992. Tumor necrosis factor in solid tumors: increased blood levels in the metastatic disease. J. Biol. Regul. Homeostatic Agents 6: 103-107.
33. Leek, R. D., R. Landers, S. B. Fox, F. Ng, A. L. Harris, and C. E. Lewis. 1998. Association of tumour necrosis factor α and its receptors with thymidine phosphorylase expression in invasive breast carcinoma. Br. J. Cancer 77: 2246-2251.
34. Huber, M. A., N. Azoitei, B. Baumann, S. Grünert, A. Sommer, H. Pehamberger, N. Kraut, H. Beug, and T. Wirth. 2004. NF-κB is essential for epithelial-mesenchymal transition and metastasis in a model of breast cancer progression. J. Clin. Invest. 114: 569-581.
35. Buckner, J. H., and S. F. Ziegler. 2004. Regulating the immune system: the induction of regulatory T cells in the periphery. Arthritis Res. Ther. 6: 215-222.